184 related articles for article (PubMed ID: 27067323)
1. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
Andersson JA; Fitts EC; Kirtley ML; Ponnusamy D; Peniche AG; Dann SM; Motin VL; Chauhan S; Rosenzweig JA; Sha J; Chopra AK
Antimicrob Agents Chemother; 2016 Jun; 60(6):3717-29. PubMed ID: 27067323
[TBL] [Abstract][Full Text] [Related]
2. Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.
Andersson JA; Sha J; Kirtley ML; Reyes E; Fitts EC; Dann SM; Chopra AK
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109161
[TBL] [Abstract][Full Text] [Related]
3. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection.
Andersson JA; Peniche AG; Galindo CL; Boonma P; Sha J; Luna RA; Savidge TC; Chopra AK; Dann SM
mBio; 2020 Mar; 11(2):. PubMed ID: 32156806
[TBL] [Abstract][Full Text] [Related]
4. New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague.
Fitts EC; Andersson JA; Kirtley ML; Sha J; Erova TE; Chauhan S; Motin VL; Chopra AK
mSphere; 2016; 1(6):. PubMed ID: 27981238
[TBL] [Abstract][Full Text] [Related]
5. A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.
Sha J; Rosenzweig JA; Kirtley ML; van Lier CJ; Fitts EC; Kozlova EV; Erova TE; Tiner BL; Chopra AK
Microb Pathog; 2013 Feb; 55():39-50. PubMed ID: 23063826
[TBL] [Abstract][Full Text] [Related]
6. High-throughput, signature-tagged mutagenic approach to identify novel virulence factors of Yersinia pestis CO92 in a mouse model of infection.
Ponnusamy D; Fitts EC; Sha J; Erova TE; Kozlova EV; Kirtley ML; Tiner BL; Andersson JA; Chopra AK
Infect Immun; 2015 May; 83(5):2065-81. PubMed ID: 25754198
[TBL] [Abstract][Full Text] [Related]
7. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
8. The role of the phoPQ operon in the pathogenesis of the fully virulent CO92 strain of Yersinia pestis and the IP32953 strain of Yersinia pseudotuberculosis.
Bozue J; Mou S; Moody KL; Cote CK; Trevino S; Fritz D; Worsham P
Microb Pathog; 2011 Jun; 50(6):314-21. PubMed ID: 21320584
[TBL] [Abstract][Full Text] [Related]
9. Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague.
Tiner BL; Sha J; Kirtley ML; Erova TE; Popov VL; Baze WB; van Lier CJ; Ponnusamy D; Andersson JA; Motin VL; Chauhan S; Chopra AK
Infect Immun; 2015 Apr; 83(4):1318-38. PubMed ID: 25605764
[TBL] [Abstract][Full Text] [Related]
10. Identification of small-molecule inhibitors of Yersinia pestis Type III secretion system YscN ATPase.
Swietnicki W; Carmany D; Retford M; Guelta M; Dorsey R; Bozue J; Lee MS; Olson MA
PLoS One; 2011; 6(5):e19716. PubMed ID: 21611119
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
[TBL] [Abstract][Full Text] [Related]
12. Survival protein A is essential for virulence in Yersinia pestis.
Southern SJ; Scott AE; Jenner DC; Ireland PM; Norville IH; Sarkar-Tyson M
Microb Pathog; 2016 Mar; 92():50-53. PubMed ID: 26724738
[TBL] [Abstract][Full Text] [Related]
13. A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.
Trombetta RP; Dunman PM; Schwarz EM; Kates SL; Awad HA
mSphere; 2018 Oct; 3(5):. PubMed ID: 30381352
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic Therapy of Plague: A Review.
Sebbane F; Lemaître N
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065940
[TBL] [Abstract][Full Text] [Related]
15. The plague virulence protein YopM targets the innate immune response by causing a global depletion of NK cells.
Kerschen EJ; Cohen DA; Kaplan AM; Straley SC
Infect Immun; 2004 Aug; 72(8):4589-602. PubMed ID: 15271919
[TBL] [Abstract][Full Text] [Related]
16. The in vitro and in vivo protective effects of tannin derivatives against Salmonella enterica serovar Typhimurium infection.
Reyes AWB; Hong TG; Hop HT; Arayan LT; Huy TXN; Min W; Lee HJ; Lee KS; Kim S
Microb Pathog; 2017 Aug; 109():86-93. PubMed ID: 28552635
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo assessment of Salmonella enterica serovar Typhimurium DT104 virulence.
Allen CA; Fedorka-Cray PJ; Vazquez-Torres A; Suyemoto M; Altier C; Ryder LR; Fang FC; Libby SJ
Infect Immun; 2001 Jul; 69(7):4673-7. PubMed ID: 11402014
[TBL] [Abstract][Full Text] [Related]
18. FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy.
Wang J; Sha J; Strong E; Chopra AK; Lee S
Microbiol Spectr; 2022 Oct; 10(5):e0250922. PubMed ID: 36129262
[TBL] [Abstract][Full Text] [Related]
19. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Louie A; Deziel MR; Liu W; Drusano GL
Antimicrob Agents Chemother; 2007 Aug; 51(8):2661-7. PubMed ID: 17517837
[TBL] [Abstract][Full Text] [Related]
20. The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.
Hewitt JA; Lanning LL; Campbell JL
Clin Infect Dis; 2020 May; 70(70 Suppl 1):S51-S59. PubMed ID: 32435803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
